Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Makes Its Rx Generics Business Look Right At Home

Executive Summary

Board bloc still is pushing to divest the Rx segment, though it achieved 4% volume sales growth and $6m in new product sales in the second quarter. Apparent second-quarter validation isn't enough to persuade CEO John Hendrickson to stay on.

Advertisement

Related Content

Generic Manufacturers Try To Up Their Game As US Pressure Persists
Perrigo's Return To OTC Roots Restoring Investor Confidence
Perrigo Trims Workforce, Ships Tysabri License, Stays European Course
Perrigo 'Unlocks Value' But Weak 2017 Outlook Impedes Revelry
Starboard Agreement Tilts Perrigo Toward Rx Generics Sale
Perrigo's Rx Business Looks Ready To Sell, Says Hedge Fund Investor

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099303

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel